Rohini Vanga1,2, Millie D Long3,4. 1. Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, CB #7080, Chapel Hill, NC, 27599-7080, USA. 2. Center for Gastrointestinal Biology and Disease, Chapel Hill, NC, USA. 3. Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, CB #7080, Chapel Hill, NC, 27599-7080, USA. millie_long@med.unc.edu. 4. Center for Gastrointestinal Biology and Disease, Chapel Hill, NC, USA. millie_long@med.unc.edu.
Abstract
PURPOSE OF REVIEW: We discuss the newest evidence-based data on management of ulcerative colitis (UC). We emphasize risk-stratification, optimizing medical therapies, and surgical outcomes of UC. RECENT FINDINGS: Recent medical advances include introduction of novel agents for UC. Vedolizumab, an anti-adhesion molecule, has demonstrated efficacy in moderate to severe UC. Tofacitinib, a small molecule, has also demonstrated efficacy. Data on optimization of infliximab show the superiority of combination therapy with azathioprine over monotherapy with infliximab or azathioprine alone. Data on anti-tumor necrosis factor-alpha (anti-TNF) therapeutic drug monitoring also hold promise, as do preliminary data on the dose escalation of infliximab in severe hospitalized UC. Surgical outcome data are reassuring, with new fertility data showing the effectiveness of in vitro fertilization. UC management is multi-disciplinary and changing. While novel therapies hold promise, better optimization of our current arsenal will also improve outcomes.
PURPOSE OF REVIEW: We discuss the newest evidence-based data on management of ulcerative colitis (UC). We emphasize risk-stratification, optimizing medical therapies, and surgical outcomes of UC. RECENT FINDINGS: Recent medical advances include introduction of novel agents for UC. Vedolizumab, an anti-adhesion molecule, has demonstrated efficacy in moderate to severe UC. Tofacitinib, a small molecule, has also demonstrated efficacy. Data on optimization of infliximab show the superiority of combination therapy with azathioprine over monotherapy with infliximab or azathioprine alone. Data on anti-tumornecrosis factor-alpha (anti-TNF) therapeutic drug monitoring also hold promise, as do preliminary data on the dose escalation of infliximab in severe hospitalized UC. Surgical outcome data are reassuring, with new fertility data showing the effectiveness of in vitro fertilization. UC management is multi-disciplinary and changing. While novel therapies hold promise, better optimization of our current arsenal will also improve outcomes.
Entities:
Keywords:
Management; Review; Therapeutic drug monitoring; Ulcerative colitis
Authors: Themistocles Dassopoulos; Russell D Cohen; Ellen J Scherl; Ronald M Schwartz; Lawrence Kosinski; Miguel D Regueiro Journal: Gastroenterology Date: 2015-05-27 Impact factor: 22.682
Authors: Vikas Pabby; Sveta Shah Oza; Laura E Dodge; Michele R Hacker; Vasiliki A Moragianni; Katherine Correia; Stacey A Missmer; Janis H Fox; Yetunde Ibrahim; Alan Penzias; Robert Burakoff; Adam Cheifetz; Sonia Friedman Journal: Am J Gastroenterol Date: 2014-12-16 Impact factor: 10.864
Authors: Johannan F Brandse; Gijs R van den Brink; Manon E Wildenberg; Desiree van der Kleij; Theo Rispens; Jeroen M Jansen; Ron A Mathôt; Cyriel Y Ponsioen; Mark Löwenberg; Geert R A M D'Haens Journal: Gastroenterology Date: 2015-04-25 Impact factor: 22.682
Authors: David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann Journal: Lancet Date: 2012-10-10 Impact factor: 79.321
Authors: Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts Journal: Gastroenterology Date: 2014-02 Impact factor: 22.682
Authors: Bjoern Titz; Raffaella M Gadaleta; Giuseppe Lo Sasso; Ashraf Elamin; Kim Ekroos; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng Journal: Int J Mol Sci Date: 2018-09-15 Impact factor: 5.923